Ziogas IA, Zapsalis K, Giannis D, Tsoulfas G. Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know! World J Hepatol 2020; 12(10): 709-721 [PMID: 33200011 DOI: 10.4254/wjh.v12.i10.709]
Corresponding Author of This Article
Georgios Tsoulfas, FACS, FICS, MD, PhD, Associate Professor, The First Department of Surgery, Aristotle University of Thessaloniki, 66 Tsimiski Street, Thessaloniki 54124, Greece. tsoulfasg@auth.gr
Research Domain of This Article
Surgery
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Oct 27, 2020; 12(10): 709-721 Published online Oct 27, 2020. doi: 10.4254/wjh.v12.i10.709
Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!
Ioannis A Ziogas, Konstantinos Zapsalis, Dimitrios Giannis, Georgios Tsoulfas
Ioannis A Ziogas, Konstantinos Zapsalis, Aristotle University School of Medicine, Thessaloniki 54124, Greece
Dimitrios Giannis, Center for Health Innovations and Outcomes Research (CHIOR), The Feinstein Institute for Medical Research, Manhasset, NY 11030, United States
Georgios Tsoulfas, The First Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
Author contributions: Ziogas IA and Zapsalis K contributed to this paper equally. Tsoulfas G and Ziogas IA contributed to conception and design; Zapsalis K, Ziogas IA, Giannis D, and Tsoulfas G contributed to acquisition, analysis, and interpretation of data; Ziogas IA, Zapsalis K, and Giannis D contributed to drafting of the manuscript; Ziogas IA, Zapsalis K, Giannis D, and Tsoulfas G contributed to critical revision and final approval.
Conflict-of-interest statement: All the authors would like to declare that there is no conflict of interest
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Georgios Tsoulfas, FACS, FICS, MD, PhD, Associate Professor, The First Department of Surgery, Aristotle University of Thessaloniki, 66 Tsimiski Street, Thessaloniki 54124, Greece. tsoulfasg@auth.gr
Received: June 11, 2020 Peer-review started: June 11, 2020 First decision: July 30, 2020 Revised: August 10, 2020 Accepted: September 1, 2020 Article in press: September 1, 2020 Published online: October 27, 2020 Processing time: 134 Days and 7.2 Hours
Core Tip
Core Tip: Metabolic syndrome (MS) is increasingly common in developed countries, and is associated with cardiovascular disease, hyperlipidemia, and non-alcoholic steatohepatitis. Diet, exercise, and weight loss are the milestones of conservative management. Bariatric surgery has emerged as a promising treatment in severely obese patients or in patients with MS resistant to conservative measures. Sleeve gastrectomy and Roux-en-Y gastric bypass are the most commonly performed bariatric procedures. The only definitive treatment in patients with MS and end-stage liver disease secondary to non-alcoholic steatohepatitis is liver transplantation (LT). The optimal timing for bariatric surgery, when required along with LT, has yet to be determined.
